interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Paliperidone Palmitate

Generic competition · all medicines · read 12 November 2026

Is there a generic of Paliperidone Palmitate, and who makes it?

Paliperidone Palmitate appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Paliperidone Palmitate1 dosage-form group in the Orange Book
0generic makers listed
  1. Paliperidone Palmitate appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Suspension, Extended Release, Intramuscular

Brand listed, no generic listed as marketed

Brand listed as marketed: Erzofri, Invega Hafyera, Invega Sustenna and Invega Trinza. No generic is listed as marketed.

20052010201520202025203020352040204501brand 2009data datePatent 9439906 listed to expire 26 January 2031Patent 10143693 listed to expire 5 April 2036Patent 12128049 listed to expire 26 October 2038Patent 11666573 listed to expire 24 September 2039Patent 11324751 listed to expire 7 May 2041Patent 11304951 listed to expire 7 May 2041Patent 12208100 listed to expire 7 May 2041Patent 11666697 listed to expire 24 November 2041
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 26 January 2031Patent 9439906
  • 5 April 2036Patent 10143693
  • 26 October 2038Patent 12128049
  • 24 September 2039Patent 11666573
  • 7 May 2041Patent 11324751
  • 7 May 2041Patent 11304951
  • 7 May 2041Patent 12208100
  • 24 November 2041Patent 11666697

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.